The largest surface of the human body exposed to the external environment is the gut. At this
level, the intestinal barrier includes luminal microbes, the mucin layer, gastrointestinal …

Fatty liver diseases can result from common metabolic diseases, as well as from xenobiotic
exposure and excessive alcohol use, all of which have been shown to exert toxic effects on …

Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial
pathophysiological process that cannot yet be recapitulated in a single in vitro model …

Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the
general population. The evidence base for the investigation and management of NAFLD is …

The term non-alcoholic liver disease (NAFLD) was originally coined to describe hepatic fat
deposition as part of the metabolic syndrome. However, a variety of rare hereditary liver and …

One of the major mechanisms of drug-induced liver injury includes mitochondrial
perturbation and dysfunction. This is not a surprise, given that mitochondria are essential …

Non-alcoholic steatohepatitis (NASH) represents a global health concern. It is characterised
by fatty liver, hepatocyte cell death and inflammation, which are associated with lipotoxicity …

Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and
the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG …

Nonalcoholic fatty liver disease (NAFLD) is a continuum of liver abnormalities often starting
as simple steatosis and to potentially progress into nonalcoholic steatohepatitis (NASH) …

Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the
accumulation of lipids in> 5% of hepatocytes and the exclusion of secondary causes of fat …